Board summary
Key figures
29,460
Registered population
55.8% aged 18–64
25.2%
Aged 65+
ICB 21.9% · England 17.9%
4.5%
Ethnic minority (non-White)
1.7% Asian · England 9.6%
17.1%
In IMD quintile 1
ICB 9.2% · England 21.0%
~5,142
Core20 residents (est.)
Resident basis; registered basis ~8,019 · see page 3
5,341
Hypertension register
+2.07% in 3 yrs · England +5.60%
404
SMI register
20.2% of Arun's
732
COPD register
Reviews -9.33% in 3 yrs
Forecast to 2030
5,801
Hypertension patients, 2030
+460 on today
67.0%
QRISK ≥20% on statins, 2030
+1.77pp over 3 yrs
5.5%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Respiratory annual reviews trail and contracted.
Asthma reviews are 58.5% (England 65.7%, -11.1% from 2023 to 2025, about 930 unreviewed patients) and COPD 64.6% (England 76.4%, -9.3%).
Hypertension blood pressure control trails comparators.
Under-80 BP control is 58.7% (England 67.8%, Arun 65.6%, -3.1% from 2023 to 2025), 73.9% aged 80+ (England 81.2%) and 62.5% overall.
Smoking cessation offers and SMI checks grew.
Smoking cessation offers rose +10.3 pp from 2023 to 2025 to 96.2% (England 94.2%) and SMI BP checks rose +6.6 pp to 82.1%.
Population, age and ethnicity
Patients aged 65 and over make up 25.2% alongside 39 catchment care homes
Across 29,460 registered patients, 25.2% (7,438) are aged 65+, compared to 29.2% in Arun, 21.9% in NHS Sussex Integrated Care Board, and 17.9% in England. Patients aged 0–17 comprise 19.0% (5,595), against 15.9% in Arun, 17.7% in the ICB, and 19.6% in England. Census usual residents show 95.5% White (Arun 95.8%, ICB 91.0%, England 81.1%) and a 4.5% ethnic minority share. Practice lists sum to 42,956 against the 29,460 PCN total, requiring population base reconciliation.
Age profile
65+: ICB 21.9%, England 17.9%
Ethnicity
Older people · falls rows are Arun local-authority (LA) data, not PCN
| Measure | Local | South East | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Arun LA) | 2,327 | 2,018 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 70.7% | 82.2% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 58.7% | 57.8% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Arun LA) | 1,216 | 981 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Arun LA) | 13.3 | 14.0 | 14.8 | 2022‑24 |
Deprivation and Core20
Core20 deprivation is 17.1% overall and concentrated at Fitzalan Medical Group
Core20 deprivation is 17.1% across the PCN, exceeding Arun (9.8%) and NHS Sussex Integrated Care Board (9.2%), though below England (21.0%), with an average IMD decile of 5.1. Between practices, Core20 share spans a 27.2 pp range: Fitzalan Medical Group records 27.2% (8,019 estimated patients), while Coppice Surgery records 0.0%. Denominators require reconciliation before targeting, as practice lists total 42,956 against 29,460 PCN registered patients, and resident decile 1 and 2 estimates total 5,142. Targeted Core20 outreach should focus on high-need neighbourhoods once practice list baselines are fully reconciled.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
404
SMI register
1.35% recorded prevalence
273
Learning disability register
0.92% recorded prevalence
39
Care homes, 1,348 beds
In the PCN catchment
8.9%
Provide unpaid care
Arun, Census 2021
The PCN records 404 severe mental illness patients (1.4% vs Arun 1.1%, NHS Sussex Integrated Care Board 1.1%, England 1.0%) and 273 learning disability patients (0.9% vs Arun 0.8%, NHS Sussex Integrated Care Board 0.6%, England 0.6%), alongside 39 catchment care homes with 1,348 beds; bed capacity does not establish registered resident numbers. Higher recorded prevalence than England is consistent with substantial demand for annual health checks alongside care-home liaison.
Severe mental illness: physical health checks
SMI prevalence is 1.4% (England 1.0%, 404 patients). Annual physical health checks reached 82.1% for blood pressure (England 83.4%), 81.5% for BMI (England 82.1%), and 79.5% for alcohol consumption (England 81.8%).
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
5,341
Hypertension register
+2.07%
Register growth, 3 yrs
Arun +4.55% · England +5.60%
−1.90pp
BP control, under 80
≤140/90 · −3.15pp aged 80+
+460
More patients by 2030
Forecast 5,801 (18.65%)
Hypertension case-finding and control
Recorded hypertension prevalence is 17.9% (5,341 patients), above England (15.2%) and NHS Sussex Integrated Care Board (16.3%), but below Arun (19.8%). However, blood pressure control under age 80 is 58.7%, trailing Arun (65.6%), the ICB (66.8%) and England (67.8%), having fallen 3.1% over 2023 to 2025 (England +3.2%). For patients aged 80+, control is 73.9% (England 81.2%), falling 4.1% (England +2.2%). Across practices, under-80 control is 56.1% at Fitzalan Medical Group and 61.7% at Coppice Surgery. Lower blood pressure control than comparators could reflect recall or medication titration challenges that require clinical review.
Lipids and statins
For secondary prevention in diabetes with CVD, statin therapy is 79.8%, trailing England (84.4%), Arun (81.3%) and NHS Sussex Integrated Care Board (81.3%), having fallen -1.9% over 2023 to 2025. Lower secondary-prevention coverage than comparators indicates high-risk diabetic patients are under-protected, making a focused prescribing audit the immediate priority.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 60,251 | £2.60 | £2.42 | £1.86 | £156,653 |
| Cardiovascular (all), 2025 | 80,218 | £3.11 | £3.32 | £3.33 | £249,478 |
In 2026, lipid-regulating drugs cost £2.60 per item across 60,251 items (annual spend £156,653), compared with £1.86 in England, £2.42 in NHS Sussex Integrated Care Board and £2.81 in Arun. This is £44,586 more than at England's unit cost. Higher unit cost than England could reflect formulary choices that warrant prescribing review.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
−11.10%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
−0.08%
Asthma prevalence, PCN 3-yr % change
Recorded prevalence exceeds England for asthma at 7.9% (England 6.6%, 2,242 patients) and COPD at 2.5% (England 1.9%, 732 patients). Over 2023 to 2025, asthma reviews fell 11.1% to 58.5% (England +4.4% to 65.7%), leaving about 930 unreviewed patients, while COPD reviews fell 9.3% to 64.6% (England +2.8% to 76.4%). Prescribing for ages 5–19 reached 2,161 items per 1,000 (England 1,488). Contracting review coverage amid high prevalence may reflect recall capacity constraints that warrant structured clinic prioritisation.
Cancer register and children's immunisation
The cancer register records 1,475 patients (4.9% prevalence, England 3.8%). In Q1 2025/26, 24-month childhood immunisation trails the 95.0% target: MMR dose 1 is 83.1% (England 88.3%) and 6-in-1 is 86.2% (England 92.2%). At age 5, coverage is 92.9% for MMR dose 1 and 91.4% for dose 2 (England 82.8%), a 1.5 pp difference. Lower coverage at 24 months than at age 5 could reflect scheduling delays.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
58.5%
Sussex ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~1,360
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Sussex ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Prostate | 56.6% | 53.2% | 19% | 1,668 |
| Breast | 86.1% | 85.4% | 23% | 1,400 |
| Bowel | 49.8% | 47.0% | 26% | 1,133 |
| Lung | 30.3% | 33.8% | 15% | 1,058 |
| Skin cancer | 95.3% | 87.8% | 17% | 698 |
In NHS Sussex ICB in 2022, 58.5% of cancers with a known stage (4,799 of 8,209) were diagnosed at stage 1 or 2, above England (55.3%) but 16.5 pp below the 75.0% national ambition by 2028. Staging completeness was 64.3% (England 67.0%). Closing the ICB gap requires about 1,360 extra early-stage diagnoses. System cervical early detection was 58.2% (England 67.6%). PCN cervical screening coverage in ages 25 to 49 is 63.8% (England 66.8%), dropping to 57.1% at Fitzalan Medical Group versus 73.0% at Coppice Surgery.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
In Jul 2026 (provisional), University Hospitals Sussex NHS Foundation Trust achieved 65.2% on the 62-day cancer referral to treatment standard, trailing England (71.2%), NHS Surrey and Sussex Integrated Care Board (71.5%), Portsmouth Hospitals University NHS Trust (75.2%), Royal Surrey NHS Foundation Trust (84.5%) and the 85.0% standard. The trust reached 74.0% on the 28-day faster diagnosis standard (England 79.3%, Royal Surrey NHS Foundation Trust 82.6%, Portsmouth Hospitals University NHS Trust 66.8%). While 12.9% of all diagnostic tests waited 6+ weeks (England 23.1%), colonoscopy waits reached 39.3% (England 30.8%) and flexi sigmoidoscopy reached 45.4% (England 32.1%).
| Pathways within standard (%) | Sussex | Portsmouth | Royal Surrey | Surrey and Sussex ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 74.01 | 66.81 | 82.62 | 79.29 | 79.32 |
| 31-day treatment (96%) | 76.79 | 94.78 | 96.43 | 90.45 | 92.50 |
| 62-day referral to treatment (85%) | 65.20 | 75.20 | 84.48 | 71.51 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Sussex | Portsmouth | Royal Surrey | England |
|---|---|---|---|---|
| MRI | 5.62 | 50.36 | 0.00 | 21.40 |
| CT | 8.57 | 13.06 | 0.15 | 9.92 |
| Echocardiography | 0.39 | 32.75 | 1.55 | 28.48 |
| Colonoscopy | 39.35 | 82.52 | 0.00 | 30.83 |
| Gastroscopy | 20.02 | 74.88 | 0.00 | 29.02 |
| All 15 DM01 tests | 12.95 | 51.96 | 8.82 | 23.14 |
| Community services activity | West Sussex residents | Surrey and Sussex ICB |
|---|---|---|
| Care contacts | 78,050 | 309,615 |
| Referrals | 16,015 | 66,930 |
| Patients with a contact | 19,770 | 85,660 |
Community services (residents of West Sussex), Jun 2026 (provisional). In Jun 2026 (provisional), West Sussex recorded 78,050 community care contacts across 19,770 patients, alongside 16,015 referrals. Adults aged 65+ accounted for 72.7% of all contacts (56,740). Across NHS Surrey and Sussex Integrated Care Board, 309,615 community care contacts were recorded for 85,660 patients. These experimental activity figures reflect local authority residents rather than registered PCN cohorts.
Practice variation and patient experience
Practice phone access trails England at 23.4% and 35.9% across the two surgeries
In 2025/26, QOF overall achievement was 92.3% at Coppice Surgery and 84.5% at Fitzalan Medical Group (England 92.5%). Vaccination and immunisation achievement reached 41.4% at Coppice Surgery and 19.4% at Fitzalan Medical Group across a 21.9 pp range (England 55.2%). Clinical achievement was 98.7% at Coppice Surgery and 92.1% at Fitzalan Medical Group.
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Fitzalan Medical | 91 | 27.2 | 35.9% | 68.3% | 65.6% |
| Coppice Surgery | 100 | 0.0 | 23.4% | 61.5% | 55.0% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
The PCN trails England on 17 of 25 three-year change measures
The PCN trails England on 17 of 25 three-year change measures from 2023 to 2025. Annual review rates contracted sharply: heart failure reviews fell 21.4% (England +8.7%), asthma reviews fell 11.1% (England +4.4%), and COPD reviews fell 9.3% (England +2.8%). Blood pressure control under age 80 fell 3.1% (England +3.2%). Conversely, smoking cessation offers rose +10.3 pp (England +0.1 pp) and severe mental illness blood pressure checks rose +6.6 pp (England +4.4 pp). These contrasting trajectories could reflect selective clinical recall capacity, which local audits would test.
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Heart failure reviews
Asthma reviews
COPD reviews
BP control, under 80
BP control, 80+
Smoking support (SMI)
Breast screening (53-70)
BP check (SMI)
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Arun | Asset | PCN | Arun |
|---|---|---|---|---|---|
| Care homes (catchment) | 39 (1,348 beds) | n/a | Schools (catchment) | 33 | n/a |
| Children's centres | 3 | 7 | Places of worship | 23 | 68 |
| Libraries | 3 | 7 | Homelessness support (VCS) | 0 | no data |
| Day centres (VCS) | n/a | 1 | Carers support groups (VCS) | n/a | 1 |
| Primary schools (LA maintained) | 5 | 21 | Primary academies | 9 | 19 |
| Special schools | 1 | 1 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Structured asthma and respiratory review recall
Asthma reviews are 58.5% of 2,242 patients (England 65.7%, Arun 63.2%, ICB 62.5%, falling 11.1% over 2023 to 2025, about 930 unreviewed); COPD reviews are 64.6% of 732 (England 76.4%, falling 9.3%). Moderate effort to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 2
Pharmacist-led hypertension titration and recall
Across 5,341 hypertension patients (17.9%), under-80 BP control is 58.7% (England 67.8%, Arun 65.6%, falling 3.1% over 2023 to 2025) and 80+ control is 73.9% (England 81.2%, falling 4.1%), while 86.8% have a recent reading. Moderate effort to run.
Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.
Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).
Option 3
Core20 childhood immunisation and screening recall
In Q1 2025/26 (cohort 65), 24-month MMR1 is 83.1% (England 88.3%, ICB 90.2%, 11.9 pp below the 95.0% target) and 6-in-1 is 86.2%. At Fitzalan Medical Group, age-5 MMR2 is 85.7% and cervical screening (25-49) is 57.1%. Moderate effort to run.
Evidence base: uptake is the delivery measure of the national cancer screening programme; distance to the acceptable and achievable standards is the outreach target.
Policy anchor: Shift 3: sickness to prevention; Eliminate cervical cancer by 2040.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Demographic and list base reconciliation (p2) | Aged 65+ | Neighbourhood health framework · NHS vaccination strategy | PCN |
| Targeted Core20 outreach (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| SMI physical review outreach (p4) | SMI register with a BP check in the last 12 months | MHIS · From Harm to Hope | PCN |
| Hypertension blood pressure control review (p5) | Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Toddler immunisation recall audit (p6) | MMR dose 1 coverage at 24 months | 10YHP sickness to prevention · 95% target | PCN |
| Targeted cervical screening recall (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | PCN |
| Telephony and access triage review (p9) | GPPS good overall experience of the practice | 10YHP, hospital to community | Practice |
| Option 1 · Structured asthma and respiratory review recall (p12) | Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) · COPD register | Core20PLUS5 respiratory | PCN |
| Option 2 · Pharmacist-led hypertension titration and recall (p12) | Hypertension register · Hypertension: QOF prevalence · Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN & Practice |
| Option 3 · Core20 childhood immunisation and screening recall (p12) | Core20 cohort (IMD quintile 1) · MMR dose 1 coverage at 24 months · 6-in-1 complete primary course at 24 months | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | PCN & Practice |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | ICB | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
